SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials

Disclosure: G.J. Kahaly: Research Investigator; Self; Horizon Therapeutics plc. Q. Fu: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. R.J. Holt: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. Background: The pivotal clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahaly, George J, Fu, Qianhong, Holt, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553925/
http://dx.doi.org/10.1210/jendso/bvad114.1933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553925/
http://dx.doi.org/10.1210/jendso/bvad114.1933

Ejemplares similares